BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 16952047)

  • 1. Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
    Viehl CT; Moore TT; Liyanage UK; Frey DM; Ehlers JP; Eberlein TJ; Goedegebuure PS; Linehan DC
    Ann Surg Oncol; 2006 Sep; 13(9):1252-8. PubMed ID: 16952047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
    Valzasina B; Piconese S; Guiducci C; Colombo MP
    Cancer Res; 2006 Apr; 66(8):4488-95. PubMed ID: 16618776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
    Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
    Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerating the secondary immune response by inactivating CD4(+)CD25(+) T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis.
    Quinn KM; Rich FJ; Goldsack LM; de Lisle GW; Buddle BM; Delahunt B; Kirman JR
    Eur J Immunol; 2008 Mar; 38(3):695-705. PubMed ID: 18266274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine.
    Hueman MT; Stojadinovic A; Storrer CE; Foley RJ; Gurney JM; Shriver CD; Ponniah S; Peoples GE
    Breast Cancer Res Treat; 2006 Jul; 98(1):17-29. PubMed ID: 16758122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New strategy of cancer immunotherapy: irradiation or chemotherapeutics-induced lymphopenia combined with immune reconstitution and tumor vaccine].
    Ma J; Wang YL; Hu HM; Fox BA; Si LS
    Zhonghua Zhong Liu Za Zhi; 2005 Aug; 27(8):452-6. PubMed ID: 16188138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
    Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses.
    Dercamp C; Chemin K; Caux C; Trinchieri G; Vicari AP
    Cancer Res; 2005 Sep; 65(18):8479-86. PubMed ID: 16166328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.
    Liyanage UK; Moore TT; Joo HG; Tanaka Y; Herrmann V; Doherty G; Drebin JA; Strasberg SM; Eberlein TJ; Goedegebuure PS; Linehan DC
    J Immunol; 2002 Sep; 169(5):2756-61. PubMed ID: 12193750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ CD25+ regulatory T cells control the magnitude of T-dependent humoral immune responses to exogenous antigens.
    Eddahri F; Oldenhove G; Denanglaire S; Urbain J; Leo O; Andris F
    Eur J Immunol; 2006 Apr; 36(4):855-63. PubMed ID: 16511897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma.
    Liyanage UK; Goedegebuure PS; Moore TT; Viehl CT; Moo-Young TA; Larson JW; Frey DM; Ehlers JP; Eberlein TJ; Linehan DC
    J Immunother; 2006; 29(4):416-24. PubMed ID: 16799337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
    Li J; Hu P; Khawli LA; Epstein AL
    Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy.
    Needham DJ; Lee JX; Beilharz MW
    Biochem Biophys Res Commun; 2006 May; 343(3):684-91. PubMed ID: 16563349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CD4+CD25+ regulatory T cells in viral infections.
    Vahlenkamp TW; Tompkins MB; Tompkins WA
    Vet Immunol Immunopathol; 2005 Oct; 108(1-2):219-25. PubMed ID: 16126280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F
    Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.